Organon to Acquire Forendo Pharma
Organon (NYSE: OGN), and Forendo Pharma today announced that the companies have entered into a definitive agreement, under which Organon will acquire Forendo, a clinical-stage drug development company focused on novel treatments in women’s health. Forendo is pioneering the science of intracrinology, addressing disease through a novel, tissue-specific approach. Its lead clinical compound is an investigational, potentially first-in-class oral 17β-hydroxysteroid dehydrogenase type 1 (HSD17B1) inhibitor in early clinical development for endometriosis, being evaluated for its potential effect on endometriotic lesions. Endometriosis is a common and chronic condition that affects up to 1 in 10 women of reproductive age, causes abdominal pain and is associated with infertility.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211111005620/en/
“Organon is dedicated to delivering medically significant women’s healthcare interventions, prioritizing disease areas based on her unmet needs. Endometriosis is among our highest priority areas of focus,” said Kevin Ali, Organon’s Chief Executive Officer. “Our acquisition of Forendo further demonstrates our commitment to building a pipeline of impactful treatment options for women with unmet medical needs.”
Preclinical research suggests that Forendo’s lead investigational clinical compound, FOR-6219, inhibits the conversion of low potency estrone into highly potent estradiol in endometriotic lesions ex vivo. This investigational compound is different than currently available treatments because of its potential ability to act locally in the target tissues without impacting systemic hormone levels. This potentially selective activity allows for its evaluation as a long-term treatment option for endometriosis. There are currently no long-term treatment options for endometriosis approved. FOR-6219 is entering Phase 2 clinical development.
Forendo’s pipeline also includes a preclinical program targeting polycystic ovarian syndrome (PCOS), one of the most common women’s health conditions often associated with metabolic disorders, hyperandrogenism and infertility. As there are currently no approved therapies for PCOS, this represents another priority disease area for Organon.
Risto Lammintausta, CEO of Forendo, emphasized the importance of the transaction: “This is a great opportunity for Forendo to join forces with a larger organization capable of accelerating the development of our innovative product candidates through mid and late-stage trials and, once approved, make the resulting drugs available to patients suffering from endometriosis and PCOS worldwide. Based on the preclinical data, we believe our novel therapeutic mechanisms hold promise in therapeutic areas where patients currently have limited options.”
Consideration for the transaction includes a $75 million upfront payment, assumption of approximately $9 million of Forendo debt, payments upon the achievement of certain development and regulatory milestones of up to $270 million and commercial milestones payments of up to $600 million, which together could amount to total consideration of $954 million. Completion of the transaction is subject to review under the Hart-Scott-Rodino Antitrust Improvements Act and other customary conditions. The transaction is expected to close in December 2021.
Organon is a global healthcare company formed through a spin-off from Merck, (NYSE: MRK) known as MSD outside of the United States and Canada, to focus on improving the health of women throughout their lives. Here for her health, Organon has a portfolio of more than 60 medicines and products across a range of therapeutic areas. Led by the reproductive health portfolio coupled with an expanding biosimilars business and stable franchise of established medicines, Organon’s products produce strong cash flows that will support investments in future growth opportunities in women’s health. In addition, Organon is pursuing opportunities to collaborate with biopharmaceutical innovators looking to commercialize their products by leveraging its scale and presence in fast growing international markets.
Organon has a global footprint that serves people in over 140 markets, world-class commercial capabilities and approximately 9,000 employees with headquarters located in Jersey City, New Jersey.
Forward-Looking Statement of Organon
Except for historical information herein, this news release includes “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, including, but not limited to, statements about management’s expectations about Organon’s acquisition of Forendo and the potential of FOR-6219 to become a long-term treatment option for endometriosis. Forward-looking statements may be identified by words such as “expects,” “potential,” “intends,” “anticipates,” “plans,” “believes,” “seeks,” “estimates,” “will” or words of similar meaning. These statements are based upon the current beliefs and expectations of Organon’s management and are subject to significant risks and uncertainties. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.
Risks and uncertainties include, but are not limited to, the possibility that any of the anticipated benefits of Organon’s acquisition of Forendo will not be realized or will not be realized within the expected time period; the risk that integration of Forendo will be materially delayed or will be more costly or difficult than expected; the failure to satisfy any conditions to completion of the proposed acquisition or the failure to close for any other reason; the possibility that FOR-6219 may not become a long-term treatment option for endometriosis; general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of the ongoing COVID-19 pandemic and emergence of variant strains; the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances; new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; Organon’s ability to accurately predict its future financial results and performance; Organon’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; difficulties developing and sustaining relationships with commercial counterparties; dependence on the effectiveness of Organon’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.
Organon undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in Organon’s filings with the Securities and Exchange Commission (SEC), including its registration statement on Form 10, available at the SEC’s Internet site (www.sec.gov).
Forendo is pioneering the translation of intracrinology science into first-in-class therapeutic solutions. Intracrinology enables physicians to address diseases on an unprecedented tissue-specific level. Forendo’s lead clinical compound in endometriosis is being evaluated for its potential effect on endometriotic lesions, a significant unmet need. The company’s second program is targeting polycystic ovarian syndrome (PCOS) which currently has no approved therapies. In addition to women’s health programs, Forendo has a strategic collaboration with Novartis leveraging its unique HSD17B platform in chronic liver diseases. Forendo is based in Finland and backed by Novo Seeds, Karolinska Development, Innovestor, Novartis Venture Fund, M Ventures, Vesalius Biocapital III Partners and Sunstone Life Science Ventures. For more information, please visit: www.forendo.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Prodapt Acquires UK-Based SLR Dynamics8.12.2021 15:21:00 EET | Press release
Prodapt, the leading consulting, technology & managed services provider to the Connectedness vertical, announced that it acquired SLR Dynamics, a UK-based company focused on digital engineering and automation services in the TMT industry. SLR Dynamics counts leading European and African telcos as their customers. This is Prodapt’s second acquisition for the year following its acquisition of Silicon Valley-based Innovative Logic in August. The acquisition of SLR Dynamics will strengthen Prodapt’s leadership position in the connectedness vertical. With the TMT industry accelerating digital transformation journeys using technologies like 5G, cloud, SDN/NFV, Edge Computing, IoT, and AI-ML, Prodapt’s acquisition of SLR Dynamics will help deliver enhanced value to its global customers. “I am excited to welcome Salim and the SLR Dynamics team to the Prodapt family,” said Vedant Jhaver, Chairman and CEO, Prodapt. “The capabilities of SLR Dynamics in Cloud, Security, IoT and Product design will
NielsenIQ Rises to the Omnichannel Measurement Challenge8.12.2021 15:01:00 EET | Press release
The shopper journey continually evolves as consumers have more control over what they do, see, and hear. That means the tools used to measure and analyze sales, market share and consumer behavior must also change. In an environment that continues to experience seismic shifts, measuring when, where and how consumers are buying is imperative. This allows fast-moving consumer goods (FMCG) manufacturers and retailers to anticipate trends and react faster to consumers’ needs and expectations. Although the fastest growing channel in Western Europe and North America is online, e-commerce measurement tools are largely fragmented. Users must combine data from multiple sources to get a full picture of the market. NielsenIQ is transforming the FMCG and retail industry with its innovative solutions and precise insights, which offer an integrated, accurate, complete, and more granular view of the offline and online marketplace—making it easier to analyze trends across channels. Our latest acquisiti
Proposed “European AI Act” and “Machinery Product Regulation” Will Hamper Innovation, Stifle Small Businesses and Disrupt Manufacturing, Global Robotics Leaders Warn8.12.2021 15:00:00 EET | Press release
The European Commission’s proposed AI Act and updated regulations on machinery products will cause severe damage to European small businesses, robotics companies and innovation, according to four of the most influential voices in robotics and automation. Together, the International Federation of Robotics, the VDMA Robotics + Automation Association, EUnited Robotics and REInvest Robotics urgently call on European policymakers to revisit and amend the proposals. While all four organizations embrace the European Commission’s vision to maintain safety, protect human rights and create a harmonized framework for artificial intelligence and robotics, the collective sees the following primary issues with the proposed regulations as currently drafted: The mandatory third-party certification requirements will slow tech innovation across Europe. The restrictions will hinder artificial intelligence adoption and put European companies, especially SMEs and startups, at a competitive disadvantage glo
Takeda Announces Publication of Data from SOLSTICE, a Pivotal Phase 3 Trial for LIVTENCITY™ (Maribavir) in Post-Transplant Recipients With Cytomegalovirus (CMV) Infection (Refractory, With or Without Resistance)8.12.2021 15:00:00 EET | Press release
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that the data from the pivotal Phase 3 SOLSTICE clinical trial of LIVTENCITY™ (maribavir, TAK-620) in post-transplant refractory† CMV infections with or without resistance‡ (R/R) were published in the journal of Clinical Infectious Diseases (CID). The manuscript is available online and will be included in a future print edition of CID, the official peer-reviewed journal of the Infectious Diseases Society of America.1 The SOLSTICE study primary endpoint was met, with 55.7% (131/235) of adult patients on LIVTENCITY achieving confirmed CMV DNA level below the lower limit of quantification (<LLOQ, i.e. <137 IU/mL) at the end of Study Week 8 (end of treatment phase) in comparison with 23.9% (28/117) of patients on conventional antiviral therapies (one or a combination of ganciclovir, valganciclovir, foscarnet or cidofovir); adjusted difference [95% CI]: 32.8% [22.80 to 42.74]; P<0.001.1* The key secondary e
Deutsche Post DHL Group Begins Transition at the Top: Tobias Meyer, P&P Germany Ceo, to Become Group CEO in May 20238.12.2021 14:22:00 EET | Press release
Deutsche Post DHL Group has initiated the leadership transition at the top of the company. The Supervisory Board of Deutsche Post AG has extended Frank Appel’s contract as DPDHL Group CEO until May 4, 2023. His previous contract runs until October 31, 2022. Appel will continue to serve as DPDHL Group CEO until the Annual General Meeting in 2023. Thereafter, Tobias Meyer, will take over as DPDHL Group CEO. Meyer joined the company in 2013 and has held a wide variety of positions including Head of Corporate Development, Chief Operations Officer at DHL Global Forwarding, and Head of Operations and IT at Post & Parcel Germany. He has been CEO of Post & Parcel Germany and a member of the DPDHL Management Board since March 2019. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211208005516/en/ Tobias Meyer, CEO Post & Parcel Germany (Photo: Business Wire) “In Tobias Meyer we have a recognized expert of the company taking over as DPD
Aleph Farms and WACKER Develop Open Supply Chain Solution for Proteins Used in Large-Scale Production of Cultivated Meat8.12.2021 14:09:00 EET | Press release
Aleph Farms, the first cultivated meat company to grow steaks directly from non-genetically engineered animal cells and WACKER, a supplier of leading protein production technologies, today announced the development of streamlined production processes for essential growth medium proteins to cost-effectively grow cultivated meat. These proteins, central to promoting and supporting cell growth, are not widely available in the market today and represent one of the most prohibitive expenses in scaling up cultivated meat. The agreement between WACKER and Aleph Farms is non-exclusive, meaning any cultivated meat company will be able to obtain these same affordable proteins, without using fetal bovine serum (FBS) or animal-derived ingredients. This open supply chain solution is expected to enable the industry to scale and achieve price-parity faster, eliminating a key hurdle in the commercial viability of cultivated meat. "Bringing down the cost and making suitable raw materials available at t
Brigade-M3 European Acquisition Corp.8.12.2021 13:43:00 EET | Press release
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, CAYMAN ISLANDS, JAPAN OR SOUTH AFRICA OR ANY OTHER JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE IN VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION OR WOULD REQUIRE REGISTRATION OR OTHER MEASURES. THIS ANNOUNCEMENT DOES NOT CONTAIN OR CONSTITUTE AN OFFER OF SECURITIES FOR SALE OR AN INVITATION OR OFFER TO THE PUBLIC OR FORM OF APPLICATION TO SUBSCRIBE FOR SECURITIES. This announcement is an advertisement for the purposes of Regulation EU 2017/1129 (such Regulation, together with any amendments thereto, the "Prospectus Regulation") and is not a prospectus nor an offer of securities for sale in any jurisdiction. Neither this announcement, nor anything contained herein, shall form the basis of, or be relied upon in connection with, any offer or commitment whatsoever in any jurisdiction. Investors should not purchase or s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom